First Patient Receives Lipocene's LPCN 1154 for Postpartum Depression in Phase 3 Clinical Trial
Lipocene anticipates the phase 3 trial data will support an NDA submission for LPCN 1154 to treat PPD in mid-2026, the company said.
The Weekly Dose: Cannabis, Contraceptives, and Advances in Alzheimer Disease and Gonorrhea Treatment
Clinical insights on cannabis and dementia, hormonal contraceptives and postpartum depression, the FDA-approved blood test for Alzheimer disease, more.
Reconstituted ACIP Votes Yes on Clesrovimab for Infants and Flu Shot For All, But Thimerosal Has Got to Go
The new, 7-member committee was clear on its support for the mAb for infants and the essential role of vaccination against influenza but wants an alternative preservative to thimerosal.
The Weekly Dose: Advancements in Colonoscopy, AI for Mammography, and Telemedicine Antibiotic Stewardship
Discover the latest breakthroughs in clinical research, from at-home cancer screening to AI advancements in mammography, shaping future healthcare practices.
Only Half of Patients Adherent to Antidementia Medication Regimens at 1 Year: New Meta-Analysis Results
Suboptimal adherence with antidementia drugs is associated with poorer clinical outcomes including accelerated disease progression and symptomatology.
Once-Monthly Maridebart Cafraglutide Produces Up to 20% Weight Loss in Phase 2 Trial
ADA 2025: Once-monthly dosing led to significant weight loss in adults with obesity, with or without type 2 diabetes, reported researchers.
